ncRNA-based Treatment of Neurodegenerative Diseases: Beyond 'Symptom Management' to 'Fundamental Therapy'
-
The therapeutic paradigm is shifting: the rediscovery of ncRNA Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) have long lacked disease-modifying therapies, representing a major challenge for the medical community. Recently, researchers have focused on non-coding RNAs (ncRNAs) that, while not directly encoding proteins, finely regulate gene expression. These are not mere 'junk' but have been identified as critical 'control towers' capable of halting disease progression.
-
Four core technologies underpinning innovative therapies To enable ncRNA therapeutics to exert clinical impact, the research team proposes integration with cutting‑edge engineering approaches.
- Chemical stabilization (Chemical Engineering): RNA is inherently prone to degradation. To overcome this, modifications such as Locked Nucleic Acids (LNA) and phosphorothioate (Phosphorothioate) chemistries are employed, dramatically enhancing stability and target specificity.
- Computational structure prediction: Artificial intelligence and computational biology are used to predict complex RNA secondary/tertiary structures and to analyze gene regulatory networks, thereby maximizing therapeutic efficiency.
- Exosome delivery system: Exosomes, the nanoscale vesicles released by cells, are harnessed as “nano delivery trucks.” They can traverse the blood‑brain barrier (BBB) and deliver cargo precisely to neurons, representing an innovative delivery route.
- CRISPR/Cas13 editing: The Cas13 system edits RNA directly, rather than DNA, allowing selective removal or modulation of disease‑causing ncRNAs.
- Key targets and tangible outcomes The team demonstrated therapeutic potential by focusing on specific clinical targets.
- BACE1‑AS and miR‑34a: Modulating these molecules prevented the protein aggregation that underlies dementia and produced a significant reduction in neuroinflammation within the brain.
- Outlook: From symptom relief to disease ‘halt’ Although ncRNA‑based therapies are still in early stages, the synergy between gene editing and nanotechnology is encouraging. If fully realized, this strategy could move beyond merely extending lifespan or delaying symptoms to achieving true precision medicine that completely halts the progression of neurodegenerative diseases.
Neurodegenerative diseases (NDs), including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), represent a growing global health challenge characterized by progressive neuronal loss and a lack of definitive disease-modifying treatments. This review explores the emerging potential of targeting non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and exosomal RNAs, to modulate pathogenic molecular pathways and address the underlying molecular origins of neurodegeneration. We evaluate the integration of advanced computational techniques for RNA structure prediction and gene regulatory network analysis, alongside chemical engineering strategies-such as Locked Nucleic Acids (LNAs) and phosphorothioate modifications-aimed at enhancing the stability and specificity of RNA-based molecules. Furthermore, we analyze cutting-edge delivery and editing technologies, including nanotechnology-driven solutions for precise neuronal targeting and the CRISPR/Cas13 system for direct ncRNA manipulation.The findings indicate that while challenges in delivery efficiency and long-term efficacy persist, the synergy of chemical engineering and computational modeling significantly improves the therapeutic profile of ncRNAs, with exosomal pathways offering a novel route for intercellular signaling modulation and biomarker discovery. Therapeutic interventions directed at specific clinical targets, such as miR-34a and BACE1-AS, demonstrate the capacity to influence protein aggregation and neuroinflammatory cascades. Although ncRNA-based therapies are currently in nascent stages, ongoing technological advancements in RNA editing and nanotechnology offer a transformative framework that could redefine the future of ND treatment and successfully halt disease progression rather than merely managing symptoms.
ncRNA represents a novel drug target capable of fundamentally modulating disease mechanisms, thereby driving scientific innovation. Securing effective delivery and stabilization technologies confers substantial societal value by markedly improving patients’ quality of life.